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Abstract 
      Adenosine A2A receptors have a unique cellular 
and regional distribution in the basal ganglia (BG), 
being particularly concentrated in areas richly 
innervated by dopamine (DA) such as the caudate-
putamen, otherwise called striatum, and the globus pallidus.
Adenosine A2A and DA D2 receptors are capable of 
forming functional heteromeric complexes and are 
colocalised in striatopallidal neurons. Based on the 
peculiar cellular and regional distribution of this receptor
and in line with data showing that A2A  receptor  antagonists
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improve motor symptoms of  Parkinson’s  disease  (PD)  in  animal models and  in 
clinical trials, A2A receptor antagonists have emerged as an attractive non-
dopaminergic target to improve the motor deficits that characterise PD. 
Experimental data have also shown that A2A receptor antagonists are capable of 
exerting a neuroprotective effect and do not induce neuroplasticity phenomena that 
complicate long-term dopaminergic treatments. The present review will provide an 
updated summary of results reported in the literature concerning the biochemical 
characteristics and BG distribution of A2A receptors. We subsequently aim to 
examine the effects of adenosine A2A antagonists in rodent and primate models of 
PD and L-DOPA-induced dyskinesia. Finally, conclusive remarks will be made on 
the neuroprotective effects of A2A antagonists and on the translation of adenosine 
A2A receptor antagonists in the treatment of PD. 
 
Introduction 
 Adenosine is an endogenous nucleoside, made up of the purine base adenine 
linked to ribose, present in the intra and extracellular spaces of all mammalian 
tissues where it takes part in a large number of physiological processes.  
 
 Adenosine formation critically depends on ATP breakdown and synthesis. At 
intracellular level adenosine is formed through hydrolysis of AMP by means of the 
enzyme 5’-nucleotidase, or alternatively in lower concentrations through 
hydrolysis of S-adenosylhomocysteine (SAH) by a specific hydrolase. Conversely, 
extracellular adenosine levels appear to be dependent on both intracellular 
adenosine outflow and on the degradation of extracellularly released nucleotides. 
The balance of adenosine concentrations in the intra and extracellular spaces is 
maintained by means of specialized bi-directional nucleoside transporters. 
Inactivation of extracellular adenosine is primarily mediated by uptake across the 
neuronal cell membrane, followed by either phosphorylation into AMP by 
adenosine kinase or deamination into inosine by adenosine deaminase. Another 
possible catabolic pathway is represented by a reversible reaction catalysed by 
SAH hydrolase, forming SAH from adenosine and L-homocysteine [1]. 
 
 In the Central Nervous System (CNS), adenosine is released by neurons and 
glial cells as a result of metabolic activity [1]. The normal extracellular levels of 
adenosine in the CNS are in the medium nanomolar range (30-300 nm), although 
this concentration may rise as much as one hundred-fold as a result of oxygen 
limitation, such as occurs during hypoxia or ischemia [2]. Adenosine exerts a dual 
modulatory role at either pre or postsynaptic level acting as a homeostatic 
modulator by controlling neurotransmitter release and neuronal responses [3].  
 
The adenosine receptors 
 The effects of adenosine are mediated through specific receptors belonging to 
the family of G protein-coupled receptors (GPCR) located on cell membranes and 
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characterized by the presence of seven transmembrane domains. To date, four 
different subtypes of adenosine receptors (A1, A2A, A2B, A3) have been cloned and 
characterized in several species including humans [4]. A3 and A2B receptors, which 
display a low affinity for adenosine, are thought to be stimulated only by the high 
concentrations of adenosine reached during pathological conditions (micromolar 
range) [4,5]. On the other hand, the A1 and A2A receptor subtypes bind adenosine 
with high affinity, their stimulation being involved in the physiological action of 
the neuromodulator [4]. Accordingly, A1 and A2A subtypes are the most widely 
studied among the adenosine receptors.  
 The main intracellular signalling pathways utilized by adenosine receptors involve 
the modification of cAMP levels, A1 and A3 receptors causing inhibition of adenylate 
cyclase and A2A and A2B receptors activating the enzyme [4]. Other mechanisms such 
as regulation of voltage-sensitive Ca2+ channels or G protein-dependent K+ channels, 
also participate in signal transduction by each of the adenosine receptors [4]. 
 
Distribution of A2A receptors in the brain 
 Several autoradiographic studies performed using radiolabelled ligands, in 
situ hybridization and reverse transcription polymerase chain reaction have 
shown that A1 and A2A receptors are expressed at high levels in the brain, 
although with different distributions. Whereas A1 receptors are widely 
expressed throughout the brain, A2A receptors are highly enriched in the basal 
ganglia (BG) nuclei where they play an important role in the control of motor 
behavior, a feature of particular relevance in Parkinson’s disease (PD) (Fig. 1). 
 Autoradiographic studies using different radioligands have shown high 
levels of A2A receptor in the caudate-putamen (CPu) or striatum, nucleus 
accumbens (NAc), olfactory tubercles, and the external globus pallidus (GPe) in 
rat and human brain [6-9]. Consistently, immunohistochemical studies, using 
both monoclonal antibody generated against purified recombinant human A2A 
receptor [10] and polyclonal antibody against rat A2A receptor [11] substantially 
confirmed this selective localization of the A2A receptor in rat brain. These 
findings have been substantiated by results deriving from in situ hybridization 
studies showing that in rodent, primate and human the CPu, NAc, and the 
olfactory tubercles are enriched in mRNA encoding A2A receptors [12-17].  
 Moreover, using more sensitive techniques, lower levels of A2A receptors and 
their relative mRNAs have also been shown in several other brain areas outside the 
BG such as the hippocampus, the cerebral cortex, the thalamus and the cerebellum, 
with differences being observed between humans and other animal species [8-
11,15,16]. Recently, the presence of A2A receptors has been described in detail in 
astrocytes in various brain areas [11,18]. It should be pointed out how, in spite of the 
use of different methodological approaches, all the above mentioned studies are 
consistent in describing high levels of A2A receptors in the striatum, an area 
extensively involved in the control of movement [19] (Fig. 1). 
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Figure 1. Schematic representation of regional (sagittal section of rat brain) and cellular 
localization of A2A receptor in the Caudate-Putamen (CPu) that provide the basis of 
antiparkinsonian action of A2A antagonists. As showed in this figure representing the 
two major CPu GABAergic output pathways A2A receptors are largely restricted to 
GABAergic neurons that express dopamine D2 receptors and enkephalin (enk) and 
project to the globus pallidus (GP). By contrast, GABAergic neurons  projecting 
directly to substantia nigra reticulata (SNR) are enriched in D1 receptors and dynorphin 
(dyn) and do not appreciably express A2A receptors. 
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Basal ganglia organisation and neuronal localisation 
of A2A receptors 
 To better understand the means by which adenosine A2A receptors 
influence motor functions, their role in the neuronal circuitry of BG, a group of 
brain nuclei implicated in motor function and in pathophysiology of movement 
disorders such as PD, should be clarified. As mentioned previously, A2A 
receptors are present in many BG nuclei, likely affecting motor behaviour by 
acting at different levels of the BG network. 
 The BG comprise the CPu, the GPe, internal segment of the globus 
pallidus (GPi), substantia nigra pars compacta (SNc) and reticulata (SNr) and 
the subthalamic nucleus (STN). The major neural population in the CPu is 
represented by medium-sized spiny projection neurons (MSNs), accounting for 
almost 95% of striatal neurons and using γ-amino-butyric acid (GABA) as 
neurotransmitter. The remaining 5% of striatal cells consists of aspiny 
interneurons, including GABAergic and cholinergic interneurons. The activity 
of MSNs is regulated by two main inputs: dopaminergic projection from the 
SNc and glutamatergic input from cortical, thalamic and limbic areas [20]. 
Moreover, the GABAergic spiny neurons give rise to the two main striatal 
efferent circuits: the striatonigral and the striatopallidal pathway. The neurons 
of the striatonigral, or direct, pathway contain the neuropeptides substance P 
and dynorphin (DYN) and mainly express D1 receptors; this pathway directly 
projects from the CPu to the GPi/SNr (Fig. 1).  
 On the other hand, the neurons of the striatopallidal, or indirect, pathway 
containing the neuropeptide enkephalin (ENK), predominantly express D2 
receptors; this circuit connects the striatum with the GPi/SNr via synaptic 
connections in the GPe and STN [20] (Fig. 1). DA modulates motor 
coordination and fine movements by facilitating the action of the direct 
pathway on stimulatory D1 receptors and by inhibiting indirect pathway 
function acting on inhibitory D2 receptors [20].  
 In the rat BG, A2A receptors are homogeneously distributed throughout the 
lateral (motor portion), medial (associative portion) and ventro-medial (limbic 
portion) CPu. An important peculiarity of adenosine A2A receptors is their 
expression almost exclusively on striatopallidal neurons, where they are 
colocalized and interact strictly with D2 receptors [14,17,21] (Fig. 1). In 
contrast, a very few striatonigral neurons expressing D1 receptors were found 
to co-express A2A receptors [16,17,21,22]. A2A receptor mRNA was also 
detected in striatal cholinergic interneurons [23,24]. A2A receptors are almost 
exclusively restricted to the dendritic spines of striatopallidal neurons, 
especially in the vicinity of the glutamatergic synapse. Moreover, A2A 
receptors are found in lower concentrations presynaptically on the 
glutamatergic terminals, postsynaptically around the dopaminergic synapse 
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and on glial sites [18]. In contrast, in the substantia nigra (SN) A2A receptors 
are mostly concentrated in the perikarya of the SNc and SN pars lateralis 
neurons. The STN is the BG nucleus having the lowest concentration of A2A 
receptors, their distribution being restricted to the perikarya [10].   
 
Interaction between A2A and dopamine receptors 
 In the BG a wide interaction between DA and A2A receptors has been 
described, suggesting that these latter receptors extensively modulate BG 
functionality.  
 The colocalization of adenosine A2A and D2 receptors in the striatopallidal 
neurons provides an anatomical basis for the existence of a functional 
antagonistic interaction between these receptors (Fig. 1). Results from several 
studies have shown that adenosine A2A receptors exert an excitatory influence 
on striatopallidal neurons, which is partially related to their antagonistic effect 
on D2 receptor activation [25].  
 The first biochemical evidence of an A2A/D2 interaction was shown in rat 
striatal membrane where the activation of adenosine A2A receptors decreased 
the binding affinity of D2 receptors for DA [26]. Later, the same effect was 
also demonstrated in human striatal tissue [27,28] and in different cell lines 
[29-31]. These effects are likely due to the formation of heterodimeric 
complexes between the two receptors [32]. Moreover, the A2A/D2 interaction 
seems to be more potent in the DA-denervated striatum with supersensitive D2 
receptors [33]. Consistently, stimulation of adenosine A2A receptors 
counteracts the D2 receptor-mediated inhibition of cAMP formation and D2 
receptor-induced intracellular Ca2+ responses [30,31,34]. 
 Despite the fact that A2A receptors generally couple to Gs proteins in 
peripheral tissues, Kull et al. [35] have demonstrated a coexpression of A2A 
receptors with Golf proteins in GABAergic striatopallidal neurons, moreover 
demonstrating how stimulation of A2A receptors activates Golf in rat striatal 
membrane. These findings indicate that A2A receptors may be coupled to 
specific G proteins in different areas. Thus, stimulation of D2 receptors inhibits 
adenylyl cyclase through Gi proteins, whereas stimulation of A2A receptor, 
coupled to Gs/olf proteins, activates adenylyl cyclase. This strong antagonistic 
A2A/D2 receptor interaction at the adenylyl cyclase level leads to an opposite 
regulation of the activity of cAMP-dependent protein kinase (PKA) which, in 
turn, controls the phosphorylation state and activity of various receptors, ion 
channels, phosphodiesterases and numerous phosphoproteins. Consequently, 
the regulatory activity exerted by A2A receptors on the DA and cAMP-
regulated phosphoprotein (DARPP-32), which is deeply involved in DA-
mediated signal is of particular interest. As well as the activity it exerts on 
transcription factors, such as the cAMP-responsive element binding protein 
(CREB), which controls the expression of immediate early genes. 
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 The phosphoprotein DARPP-32 is expressed in very high concentrations in 
the GABAergic efferent neurons and can be phosphorylated into two different 
threonin (Thr) residues, namely Thr-34 and Thr-75, resulting in an amplification or 
inhibition of the PKA signal transduction, respectively [36-38]. Stimulation of A2A 
receptors produces, in rat striatal slices, phosphorylation of DARPP-32 at Thr-34 
and dephosphorylation of DARPP-32 at Thr-75 through cAMP accumulation and 
PKA stimulation [39-42]. Consistently, Thr-34 phosphorylation of DARPP-32 
induced by A2A receptor stimulation was found to be completely counteracted by 
D2 receptor agonists [41]. Moreover, studies in mice bearing a genetic deletion of 
DARPP-32 confirmed the involvement of this phosphoprotein in A2A receptor 
signalling, revealing an attenuation of the motor-stimulant effects induced by the 
non selective adenosine receptor antagonist caffeine as well as by the selective A2A 
antagonist SCH 58261 [42] (Fig. 2).  
 Another highly relevant issue in the regulation of signal transduction by 
A2A receptors is represented by the regulation of CREB activity. Thus, A2A-
mediated induction of cAMP releases the catalytic subunits of PKA, which 
diffuse into the nucleus and induce cellular gene expression by 
phosphorylating CREB at a specific serine residue (Ser-133) [43]. In Chinese 
hamster ovary cells cotransfected with the A2A and D2 receptor cDNAs, 
stimulation of A2A receptors produced a high increase in cAMP formation and 
phosphorylation of CREB, followed by an induction of c-fos mRNA [29]. 
Quinpirole, a selective D2/D3 agonist, dose-dependently counteracted these 
effects, achieving a complete blockade, at low concentrations, of the D2 
agonist [29]. Accordingly, a variety of in vivo studies supports the reciprocal 
antagonistic influence of A2A and D2 receptor in the induction of immediate 
early-gene expression (e.g., c-fos, zif/268, NGFI-B and jun-B) [34, 44-49]. 
Despite the above findings, it has however been shown that stimulation, as 
well as blockade, of adenosine A2A receptors induces behavioral and 
biochemical responses in mice lacking D2 receptors, thus suggesting that 
adenosine A2A receptor actions can occur, at least in part, independently from 
DA [50-52].  
 In-depth knowledge of the biology of the A2A receptor with specific 
concern for its molecular interactions with receptors for different 
neurotransmitters was reached with the discovery of functional heteromeric 
receptor complexes (receptor mosaics) formed by the A2A receptor with other 
GPCRs, such as D2 and glutamate mGlu5 receptors. This finding constituted a 
considerable step forward in adenosine neurobiology and suggested new ways 
of influencing the regulation of neuronal activity by A2A receptor manipulation 
[53]. A number of new approaches have provided convincing evidence for the 
existence of heteromeric receptor complexes; these include complementary 
chimeras, coimmunoprecipitation with differentially epitope-tagged receptors, 
the  use  of  sodium sulphate-polyacrylamide    gel electrophoresis (SDS-PAGE), 
Annalisa Pinna et al. 198
                      SCH 58261 
 
 
              KF 17837    KW 6002  
 
    SCH BT2  
 
Figure 2. Chemical structures of selective adenosine A2A receptor antagonists. 5-amino-7-
(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (SCH 58261); 
(E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine (KF 17837); (E)-1,3-dietyl-8- 
(3,4-dimethoxystyryl)-7-methyl-xantine (KW 6002); (2-furan-2-yl-7-3{4[4-(4-
methylpiperazine-1-sulfonyl)phenylethyl}-7H-pyrazolo[4,3][1,2,4]triazolo-[1,5-c]pyrimidin-
5-ylamine (SCH BT2). 
 
often in combination with covalent cross-linking, and finally biophysical 
methods, namely bioluminescence resonance energy transfer (BRET) and 
fluorescence resonance energy transfer (FRET). Indeed, coimmuno-
precipitation studies have demonstrated the existence of constitutive A2A/D2 
complexes at colocalization sites [31,54,55]. Recently, direct physical evidence 
for A2A/D2 heteromers as well as A2A homodimers within the plasma 
membrane was provided by FRET and BRET analyses, indicating less than 10 
nm separating the receptors [32,56].  
 One functional implication of this intramembrane receptor/receptor 
interaction through heteromerization is the reduction of the high affinity 
agonist state of D2 receptors. An additional consequence is the counteraction of 
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D2 receptor G protein coupling, since A2A receptor agonists counteract the GTP 
analog-induced appearance of D2 receptors in the high-affinity state through an 
action independent of the GTP binding site [53,57]. Thus, the essence of this 
A2A/D2 receptor heteromerization may be to convert the D2 receptor into a state 
of strongly reduced functional activity. In line with this view, A2A receptor 
activation counteracts D2 receptor-induced intracellular Ca2+ responses [30] 
and D2 receptor-mediated inhibition of cAMP formation [29,31]. Moreover, 
evidence for functional A2A/D3 heteromers has recently been obtained in 
cotransfected A2A/D3 cells using FRET where A2A activation reduces the 
affinity of D3 agonist binding sites as well as D3 signalling [58].  
 A2A receptors have also been found to interact with non-dopaminergic 
receptors such as the mGlu5 receptor. Evidence attesting how, by combining the 
stimulation of A2A receptors and group I mGlu, including mGlu5 receptors, the 
affinity of the D2 receptor agonist binding sites in striatal membranes could be 
synergistically reduced [59,60] was followed by physical (coimmunoprecipitation) 
evidence that A2A and mGlu5 receptors form heteromeric complexes [61]. These 
observations were supported by the high degree of A2A and mGlu5 colocalization 
in striatal neurons in primary cultures and in glutamatergic nerve terminals in the 
striatum [54,62]. Coactivation of the A2A and mGlu5 receptors caused a synergistic 
interaction at the level of c-fos expression and on extracellular signal-related kinase 
(ERK) as well  on DARPP-32 phosphorylation, indicating a possible role for this 
heteromeric complex in striatal plasticity [61,63]. Combined A2A and mGlu5 
receptor activation may also produce synergistic cellular effects on striatal output 
neurons in vivo, as demonstrated by a greater than additive increase in GABA 
release from the ventral striatopallidal neurons after local perfusion with both A2A 
and mGlu5 agonists [64]. 
 The finding of heteromeric A2A/D2 complexes has added to the substantial 
evidence for antagonistic molecular, cellular, electrophysiological and behavioural 
interactions between A2A and D2 receptors, strongly supporting the logical basis for 
antiparkinsonian strategies that simultaneously block adenosine A2A and stimulate 
DA (D1 and D2) receptors [26,65-68]. Based on these premises therefore, it is 
highly probable that a successful treatment with A2A antagonist monotherapy in the 
early stages of the PD when residual endogenous DA elicits tonic D2 receptor 
activation could be achieved. In the same way, the discovery of functional 
A2A/mGlu5 receptor interactions and heteromeric A2A/mGlu5 complexes supports 
recent data reported concerning the synergistic antiparkinsonian potential of 
combining A2A and mGlu5 antagonists [69-71].  
 
Parkinson’s disease 
 PD is an age-related neurodegenerative disorder characterized by the 
progressive and irreversible loss of neurons from specific areas of the brain, 
resulting in movement deficits.  
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 The cardinal motor features of PD are bradykinesia (slow movement and 
difficulty in initiation movement), muscle rigidity, resting tremor, postural 
instability and gait impairment [72]. These symptoms are usually manifested 
asymmetrically, initially affecting one body segment or half-body. Reduced 
facial expression, decreased eye-blinking and hypophonia are among the 
earlier manifestations. The onset of postural and gait disturbances usually 
follows this intermediate stage, often representing a major source of disability 
[73].  
 Strictly speaking, the term akinesia is used to indicate absence of 
movement, but in PD it usually refers to slowness in movement execution 
(bradykinesia) or poverty of spontaneous movements (hypokinesia). PD is 
characterised by a reduction in the rate and amplitude of movements. 
Bradykinesia may significantly impair the quality of life due to the length of 
time required to perform everyday tasks [74].  
 Rigidity is an increase in the tone of passive muscle groups that extends 
throughout the range of movement. This is clinically expressed as resistance in 
muscle groups in obtaining complete muscular relaxation. The most typical 
feature of rigidity is an increased resistance to passive movement of patient’s 
limbs usually associated with a cogwheel phenomenon [75]. 
 Tremor in PD is typically manifested at rest, tending to disappear when 
voluntary movement is performed. Tremor may be intermittent and is 
increased by stress or by manoeuvres involving concentration. [76]. 
 Postural instability and gait disturbance appear at a later stage of the 
disease when postural reflexes required to maintain the centre of gravity are 
affected. This is associated with loss of balance and falling. As the disease 
progresses, freezing begins to appear. Initially, this comprises start hesitations, 
in which patients become frozen when trying to initiate gait, when turning or 
when passing through narrow spaces [73]. 
 Non-motor features of PD abnormalities on affectivity and cognition occur 
frequently; patients may become passive or very quiet, with lack of initiative 
and slower cognitive processes. Depression can occur at any stage of the 
disease, whereas dementia is significantly more frequent (30%) in PD 
especially in older patients [77,78]. 
 Prodromic symptoms of PD begin to emerge when there is a 40-60 % 
reduction of nigral neurons and striatal dopamine, but become clinically manifest 
when nigrostriatal DA loss reaches around 70-80 % [79,80]. In the initial stages 
of disease evolution, the neurodegenerative process is mainly confined to 
dopaminergic fibers innervating the dorsolateral putamen and, therefore, clinical 
manifestations primarily affect motor features. As the disease progresses, DA 
loss extends throughout the entire striatum, often affecting other brain regions 
such as the cerebral cortex, brainstem and spinal cord [73]. 
 PD is observed in more than 1% of individuals over the age of 65 [81]. 
The specific aetiology of the disease is mainly unknown and the manifestation 
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of symptoms probably stems from both genetic and environmental abnormalities 
(vulnerability factor) and epigenetic stimuli such as oxidative stress, 
mitochondrial dysfunction and excitotoxicity, which are normally tolerated but 
that might become particularly harmful in predisposed individuals causing the 
specific deterioration of the nigrostriatal dopaminergic pathway [82,83]. 
 The pathogenesis of PD stems from the progressive preferential 
degeneration of melanized neurons of the SNc which innervate the striatum. In 
addition to the degeneration of dopaminergic neurons, the formation of inclusion 
bodies of proteins aggregates (Lewy bodies) represents a peculiar consistent 
hallmark of the disease [84]. Changes in the SNc are most pronounced in the 
ventro-lateral region. Neurodegenerative modifications can also be detected in 
the locus ceruleus, nucleus basalis of Meynert, peducolopontine nucleus (PPN), 
cerebral cortex and spinal cord. The biochemical peculiarity of PD comprises a 
reduction of striatal DA with changes being most pronounced in the postero-
lateral putamen, region that receives innervation from the ventro lateral part of 
the SNc [85]. Changes in serotoninergic, noradrenergic, glutamatergic and 
cholinergic neurotransmitter can also be observed.  
 Briefly, the DA deficiency in CPu reduces activation of DA receptors 
resulting in attenuated inhibition of the indirect pathway neurons and in a 
decreased excitation of the direct pathway neurons. The reduced inhibition of 
the indirect pathway leads to disinhibition of the STN and increased excitation 
of the GPi/SNr neurons, whereas decreased activation of the direct pathway 
causes a reduction in its inhibitory influence on the GPi/SNr. The net result is 
an excessive activation of the BG output neurons accompanied by excessive 
inhibition of motor systems, leading to parkinsonian motor features [73]. 
Moreover, DA depletion induces many secondary changes which affect 
neuronal loops connecting the BG, thalamus and cortex, including the 
glutamate-induced overexcitation of neurons localized in the STN and 
projecting to SNr/GPi [73,86]. This leads to an increase in the activity of the 
nigro/GPi GABAergic pathway [20,73] which inhibits the thalamus and PPN. 
Finally, inhibition of the PPN induces abnormal behaviour of spinal neurons 
which participate in increased muscle tone [75,87]. 
 
Pharmacological treatment of parkinsonian motor disabilities 
and the therapeutic potential of A2A receptor antagonists 
 Since parkinsonian motor symptoms occur as a consequence of DA 
depletion in the BG [88], DA replacement strategies represent the main 
therapeutic approach used to counteract PD motor impairment: consequently, 
the DA metabolic precursor L-DOPA (L-3,4-dihydroxyphenilalanine) is 
currently the most widely used and effective antiparkinsonian drug. Enzymatic 
decarboxylation converts L-DOPA into DA which, by acting on dopaminergic 
receptors in the BG, facilitates movement initiation and execution [89], thus 
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reducing PD motor disabilities. Even though L-DOPA is considered the “gold 
standard” treatment for PD, its use is not devoid of disadvantages which 
reduce the therapeutic potential of the drug [90-92].  
 The main limitation of long-term use of L-DOPA in PD treatment is 
represented by the progressive reduction of the drug’s efficacy in counteracting 
parkinsonian motor symptoms, a condition commonly reported as “wearing off”. 
During “wearing off”, L-DOPA administration relieves PD motor impairment 
for a limited period of time, usually a few hours, after which akinesia and rigidity 
are once again manifested. Moreover, prolonged use of L-DOPA is associated 
with the onset of dyskinesias and abnormal involuntary movements, which are 
highly disabling for patients, and with fluctuations of L-DOPA motor effects, 
also known as “on/off” phenomenon. During “on/off” phenomena patients may 
rapidly pass from a condition in which L-DOPA has no effect to one in which L-
DOPA counteracts PD symptoms whilst at the same time inducing dyskinesias 
and abnormal involuntary movements. Finally, the increase of both peripheral 
and central DA levels produced by L-DOPA may induce adverse effects such as 
nausea, orthostatic hypotension, hallucinations and mental confusion [93,94].  
 On the basis of the above issues, it is commonly accepted that L-DOPA 
should be used sparingly in order to limit its side effects and delay the onset of 
“wearing off” and “on/off” phenomena, as well as of dyskinesias. Thus, L-
DOPA is often administered in combination with other drugs, such as direct 
DA agonists, anticholinergics and agents acting on DA catabolism (MAO-B 
and COMT inhibitors), to reduce the dose of L-DOPA capable of relieving PD 
motor impairment. However, the majority of drugs currently associated to L-
DOPA are characterised by either an unsatisfactory efficacy on parkinsonian 
motor symptoms, often limited to the early stages of the disease, or several 
adverse effects limiting their therapeutic use. Therefore, particular effort has 
been put into the discovery of new drugs to be used, as monotherapy or in 
combination with L-DOPA, in PD treatment. 
 Over recent years, adenosine A2A receptor antagonists have emerged 
among new drugs as the best candidates for PD therapy. As described above, 
adenosine extensively interacts with dopaminergic transmission [95-97] 
modulating the genesis and expression of movement [89], and experimental 
evidence strongly accounts for a beneficial effect of A2A antagonists on PD 
symptoms. Moreover, the brain localization of A2A receptors restricted to the 
BG would result in a reduced incidence of non-motor central effects by A2A 
blockade. In addition, A2A antagonists have been shown not to exert excessive 
peripheral adverse effects, being generally well tolerated [98]. Another feature 
which renders these drugs very attractive as possible antiparkinsonian agents is 
their neuroprotective potential, which has been demonstrated in rodent models of 
PD neurodegeneration and seems to suggest a preventive action for A2A 
antagonists on PD onset and development [99-101].  
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 The structures of the most widely used A2A antagonists are reported in 
Figure 2.  
 The remaining part of this chapter will summarize the motor effects of A2A 
antagonists observed in animal models of PD as well as in clinical trials 
performed to date. Moreover, data demonstrating the protective effect of A2A 
antagonists on animal models of parkinsonian neuronal degeneration will be 
reported. 
 
Effects of adenosine A2A antagonists in animal models 
of Parkinson’s disease 
Acute effects on motor disability: Animal models 
 The study of the behavioural effects of adenosinergic ligands in 
experimental rodents has provided the first evidence that adenosine is involved 
in the control of movement. Several reports have shown that non selective 
adenosine blockers, like caffeine and theophylline, stimulate motor activity in 
rats and mice [102,103], an effect that has been demonstrated to be mainly a 
consequence of A2A receptor blockade [104,105]. The crucial role of A2A 
receptor in the modulation of motor behaviour has been further confirmed by 
studies employing selective ligands towards this receptor. In particular, 
inhibition of motor behaviour has been observed following administration of 
the A2A agonist CGS 21680 [106-108], whereas the A2A antagonist SCH 58261 
was found to stimulate motor activity [42,47,109]. Interestingly, a beneficial 
effect on motor impairment by A2A receptor blockade has been demonstrated 
in several animal models of PD, including counteraction of catalepsy and 
modulation of rotational behaviour in rodents, as well as reversion of motor 
impairment in primates (Tab. 1).  
 Catalepsy is a condition commonly induced in rats and mice by 
administration of different pharmacological agents, such as neuroleptics, 
cholinomimetics or the monoamine-depleting agent reserpine. Catalepsy is 
characterized by akinesia associated to a hypofunctionality of the striatal DA 
system, which is believed to mimic that observed in PD [110]. Drugs 
commonly used in PD treatment are known to counteract catalepsy [111,112], 
therefore reversion of catalepsy can be considered as a valuable experimental 
tool to investigate the antiparkinsonian properties of new drugs.  
 A wide number of A2A receptor antagonists have been demonstrated to 
effectively counteract catalepsy in rodents, reducing its severity and duration, 
thus accounting for an amelioration  of parkinsonian motor impairment by 
these drugs [113-116] (Tab. 1). Interestingly,  potentiation of the anticataleptic 
effect of L-DOPA has been described following its coadministration with the 
A2A antagonists KF 17837 and KW 6002 [113,114], indicating the existence of a 
synergistic interaction between L-DOPA and A2A antagonists (Fig. 2 and Tab. 1). 
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Table 1. Summary of the effects of A2A antagonists in animal models of Parkinson’s 
disease. 
 
Experimental Model Effects 
Rat 6-OHDA lesion (acute)  
[122-125] 
9 Potentiation of contralateral  
    rotational  behaviour        
    stimulated by L-DOPA and DA agonists  
Rat haloperidol-induced  
catalepsy (acute) 
[113-116] 
9 Reversal of catalepsy 
9 Potentiation of L-DOPA anticataleptic effect
Rat tremulous jaw movements 
(acute) [166,167] 
9 Counteraction of parkinsonian-like tremor 
Rat haloperidol-induced muscle 
rigidity (acute) [171,172] 
9 Amelioration of parkinsonian-like muscle  
    rigidity 
Primate MPTP lesion (acute) 
[131-133] 
9 Reversal of motor disability 
9 Amplification of L-DOPA beneficial effects 
    on motor  impairment  
Rat 6-OHDA lesion (chronic) 
[147,151] 
9 No sensitization to L-DOPA-induced 
    contralateral  rotational behaviour 
9 Reversal of the progressive shortening of 
    L-DOPA-induced contralateral rotational 
    behaviour 
Primate MPTP lesion (chronic) 
[131-133,151] 
9 Lack of dyskinetic effects  
9 Lack of worsening of L-DOPA-induced 
    dyskinesia  
9 Delay of apomorphine dyskinetic effects  
Early-genes in 6-OHDA-lesioned 
rats (acute) [122-124] 
9 Potentiation of c-fos expression stimulated  
    by L-DOPA and DA agonists 
Peptides and GAD 67 mRNA  
in 6-OHDA–lesioned rats  
(chronic) [158,159] 
9 Attenuation in the increase of  
    enkephalin, dynorphin and  
    GAD 67 mRNA compared to  
    L-DOPA full  dose 
Receptors in 6-OHDA-lesioned rats
(chronic) [151,161] 
9 Reduction of L-DOPA- 
    stimulated  phosphorylation  
    of  AMPA receptors 
Neuronal survival and DA levels 
MPTP treated mice (acute and  
chronic) and in 6-OHDA-lesioned 
rats (acute) [99,195-198] 
9 Reduced parkinsonian-like degeneration of  
    dopamine SNc neurons 
9 Attenuation of the decrease in striatal 
    DA contents 
 
 In agreement with observations made in the catalepsy model, A2A receptor 
antagonists displayed motor facilitatory activity in animals rendered parkinsonian 
by the administration of dopaminergic neurotoxins, like 6-hydroxydopamine (6-
OHDA) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Such neurotoxins 
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produce a degeneration of mesencephalic dopaminergic neurons, mimicking that 
occurring in idiopathic PD and resulting in the presence of parkinsonian-like  
symptoms (akinesia, bradykinesia etc.) in the treated animals, thus providing 
valuable and reliable PD models [110,117]. 
 The rat 6-OHDA model is induced by the unilateral medial forebrain bundle 
or SNc infusion of this neurotoxin leading to a functional unbalance of the 
dopaminergic striatal terminal and, consequently, to unilateral motor impairment 
which is typically expressed by rotational behaviour upon administration of 
dopaminomimetic drugs [118,119]. Indeed, it is well established that the ability 
of a specific drug to induce contraversive rotational behaviour, as well as to 
potentiate the rotational behaviour stimulated by DA receptor agonists, can be 
assumed to be a parameter reflecting its antiparkinsonian activity [117,120].  
 Acute administration of the A2A agonist CGS 21680 to unilaterally 6-
OHDA-lesioned rats has been demonstrated to significantly reduce rotational 
behaviour induced by L-DOPA and by either D1 or D2 DA receptor agonists 
[121]. In contrast, acute administration of the A2A antagonist SCH 58261 to 6-
OHDA-lesioned rats has been shown to significantly potentiate rotational 
behaviour induced by L-DOPA and by either D1 or D2 DA receptor agonists 
[122-124] (Tab. 1). Similarly, an enhancement of rotational behaviour stimulated 
by L-DOPA or apomorphine was observed following acute A2A receptor 
blockade by KF 17837 or KW 6002 [125] (Tab. 1). Behavioural findings have 
been supported by neurochemical data showing an enhanced responsiveness to 
dopaminergic stimuli by striatal neurons. In particular, acute SCH 58261 
administration amplified the expression of the immediate early gene c-fos, an 
index of neuronal activation [126], stimulated in the dopamine-denervated 
striatum by L-DOPA as well as direct DA agonists [122-124] (Tab. 1).  
 Reversal of motor impairment by A2A antagonists has also been observed 
in MPTP-treated non human primates. MPTP-induced parkinsonism is 
considered as the best animal model of PD, due to the anatomical and 
functional similarities existing between dopaminergic neurodegeneration 
observed in idiopathic PD and MPTP intoxication [127-129]. Furthermore, non 
human primates treated with MPTP display a large number of motor symptoms 
which accurately mimic those typical of human PD [130].  
 The A2A antagonist KW 6002 acutely increased locomotor activity and 
reversed motor disabilities in common marmosets and cynomolgus monkeys 
previously administered with MPTP [131-133] (Tab. 1). Moreover, similar to 
findings reported in other animal models of PD, a synergistic interaction between 
A2A antagonists and L-DOPA, as well as dopaminergic agonists, on motor 
disability has been observed in MPTP-treated common marmosets [132] (Tab. 1). 
 Regarding the mechanism whereby A2A antagonists counteract motor 
impairment in PD animal models, solid evidence accounts for a pivotal role for 
the opposite interactions between A2A and D2 receptors. Thus, A2A receptor 
Annalisa Pinna et al. 206
antagonists, by acting at striatopallidal neuronal level, enhance D2-mediated 
effects. Moreover, A2A receptor blockade indirectly amplifies the effects 
produced by stimulation of D1 receptors located in the striatonigral neurons 
[122,123]. Thus, the facilitatory effect produced by A2A antagonists on DA 
transmission may result in motor stimulation, explaining the beneficial activity 
of these drugs on parkinsonian-like motor impairment.  
 The finding that the motor effects of A2A antagonists are at least in part 
independent of D2 receptors [50] suggests that alternative mechanisms, in 
addition to the interaction between A2A and DA receptors might be involved in 
the motor facilitating activity of A2A antagonists. Indeed, blockade of A2A 
receptors located on cholinergic interneurons has been shown to reduce the 
efflux of acetylcholine in the striatum [134,135], whereas electrophysiological 
data indicate that A2A receptors modulate GABA release from axon recurrent 
collaterals and terminals of striatopallidal neurons, regulating the activity of 
the striatopallidal pathway [136,137]. This effect has been suggested to be 
implicated in the motor facilitating effects of A2A antagonists [138], since an 
altered functionality of the striatopallidal pathway contributes to the 
production of PD motor symptoms [139,140]. Furthermore, interactions 
between A2A and mGlu5 receptors have also been implicated in the effects of 
A2A antagonists in PD animal models [69,71].  
 On the basis of the highly selective expression of A2A receptors on 
striatopallidal neurons [21], the striatum is considered the main locus in which 
A2A antagonists counteract PD motor impairment (Fig. 1). The crucial role of 
the striatum in the effects of A2A antagonists has been confirmed by studies 
showing that the intrastriatal infusion of the A2A antagonist MSX-3 effectively 
reversed catalepsy induced by D1 or D2 receptor antagonists [141]. 
Interestingly, recent evidence obtained in 6-OHDA-lesioned rats has 
demonstrated a potentiation of L-DOPA-induced rotational behaviour 
following infusion of the A2A antagonist SCH BT2 [142] (Fig. 2) into the GP, 
the output nucleus of the striatopallidal neurons [143]. This latter finding is of 
particular interest due to the implication  that besides the well documented role 
of the striatum in mediating motor facilitation produced by A2A antagonists, 
extrastriatal circuits may also be involved in this effect.  
 To summarize, findings obtained in animal models of PD provide strong 
indications that A2A antagonists exert antiparkinsonian activity. Notably, 
synergistic interactions between L-DOPA and A2A antagonists have been 
described in different experimental paradigms, suggesting that these drugs 
might potentially be coadministered with L-DOPA in order to potentiate its 
motor stimulant effects. Furthermore, the results about the mechanisms and 
sites of action suggest that A2A antagonists modulate BG functionality in a 
wide and complex fashion. In particular, evidence postulating the influence 
exerted by A2A   receptors on      neurotransmitters such       as     acetylcholine, GABA 
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and glutamate, which are critically involved in the pathogenesis of PD [144-
146], is of great interest in the light of new therapeutic approaches employing 
A2A antagonists in combination with drugs acting on the above 
neurotransmitters in counteracting PD.   
 
Chronic effects on motor disability and on dyskinesia: Animal 
models 
 Consistent with findings reported following acute administration, chronic 
A2A antagonists have been demonstrated to effectively ameliorate motor 
deficits in parkinsonian rats and primates and, in addition, to not  produce 
tolerance to their motor stimulant effects (Tab. 1).  
 The persistence of the motor effects of A2A antagonists has been described 
in both rats and primates chronically administered with these drugs. In 6-
OHDA-lesioned rats, the potentiation of the intensity of L-DOPA-induced 
rotational behaviour elicited by acute SCH 58261 has been observed even after 
a prolonged administration regimen (up to 14 days) of the A2A antagonist 
[147]. Accordingly, in MPTP-treated common marmosets chronic (21 days) 
treatment with KW 6002 produced a relief of parkinsonian motor disability 
with no sign of tolerance to this effect [131]. 
 Tolerance is usually observed in rodents following long-term exposure to 
non selective adenosinergic blockers like caffeine and theophylline which act 
on both A1 and A2A receptors [102,148]. Interestingly, cross-tolerance between 
caffeine and the selective A1 receptor antagonist CPT has been reported, 
whereas no changes in the motor stimulant effects of the A2A antagonist MSX-
3 have been described in caffeine-tolerant rats [108]. Thus, it has been 
suggested that A1, but not A2A, receptors are increasingly involved in the 
development of tolerance to adenosinergic ligands, thereby justifying the 
results observed in parkinsonian animals chronically administered with A2A 
antagonists. The absence of tolerance to the motor stimulant effects of A2A 
antagonists is of paramount interest in a condition requiring a long-term 
pharmacological treatment such as PD, in which drugs capable of retaining their 
motor facilitating properties over a chronic administration regimen are required. 
 A major outcome emerging from studies on chronic A2A antagonists is 
represented by results reported with regard to motor fluctuations and 
dyskinesia in animals coadministered with A2A antagonists and L-DOPA. 
 Studies in 6-OHDA-lesioned rats have shown that the duration of 
rotational behaviour elicited by L-DOPA is progressively reduced during 
chronic administration of the drug, a phenomenon that is thought to reproduce 
the L-DOPA “wearing off” observed in humans [149,150]. Coadministration 
of the A2A antagonist KW 6002 prevented the shortening of rotational 
behaviour, reflecting a potential beneficial influence of A2A blockade on L-
DOPA “wearing off” [151] (Tab. 1). Despite the reduced duration, the 
Annalisa Pinna et al. 208
intensity of rotational behaviour induced by L-DOPA in 6-OHDA-lesioned 
rats undergoes a progressive increase (sensitization) during long-term 
administration. Sensitization of rotational behaviour is thought to mimic 
dyskinetic effects elicited by L-DOPA, representing a rat model of L-DOPA-
induced dyskinesia [152,153]. In this paradigm, interesting results concerning 
the modulation of dyskinesias by A2A receptor blockade have been obtained 
comparing the rotational behaviour elicited by long-term administration of a 
higher dose of L-DOPA with an equipotent combination of a lower dose of L-
DOPA plus the A2A antagonist SCH 58261. Although both L-DOPA (high 
dose) and L-DOPA (lower dose) plus SCH 58261 produced a comparable 
degree of rotations on the first administration, sensitization of rotational 
behaviour was observed in response to chronic L-DOPA alone but not to 
chronic L-DOPA plus SCH 58261 [147] (Tab. 1). The stable response 
observed after long-term L-DOPA plus SCH 58261 suggests that the 
association between the two drugs represents a treatment with low dyskinetic 
potential. Interestingly, this hypothesis has been strengthened by studies 
showing that genetic deletion of the A2A receptor  prevents the sensitization of 
rotational behaviour stimulated by L-DOPA in 6-OHDA-lesioned mice [154].    
 The results obtained in MPTP-treated primates confirm and further extend 
those deriving from 6-OHDA-lesioned rats. First, A2A antagonists do not 
induce dyskinesia per se, since administration of KW 6002 to parkinsonian 
primates relieved motor disability without stimulating abnormal movements 
[131,133] (Tab. 1). Second, in MPTP-treated marmosets previously exposed to 
chronic L-DOPA in order to develop dyskinesia, motor stimulation induced by 
KW 6002 was not associated with an exacerbation of dyskinetic movements 
[131] (Tab. 1). Furthermore, no sign of apomorphine-induced dyskinesia has 
been observed in parkinsonian cynomolgus monkeys chronically treated with a 
combination of apomorphine and KW 6002 [151]. Interestingly, if KW 6002, 
but not apomorphine, administration was interrupted, primates previously 
treated with KW 6002 displayed apomorphine-induced dyskinesia only 10-12 
days after KW 6002 discontinuation, thus accounting for a potential preventive 
effect  of A2A receptor blockade on the development of dyskinesia [151] (Tab. 1). 
 Despite the effects reported on dyskinesia onset in rats and primates, it 
should be noted that no study has yet demonstrated the ability of A2A 
antagonists to revert an already established dyskinesia in animal models. 
Nevertheless, experimental evidence suggests that A2A antagonists associated 
with a low non-dyskinetic dosage of L-DOPA may achieve satisfactory results 
in motor stimulation, whilst at the same time limiting the severity of L-DOPA-
induced dyskinesia. It has been shown that in MPTP-treated common 
marmosets previously rendered dyskinetic by chronic L-DOPA, the relief of 
motor impairment produced by an optimal dose of L-DOPA presenting a high 
dyskinetic potential was adequately mimicked by the combination of  KW 6002 
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plus a suboptimal dose of L-DOPA which, on the contrary, was associated 
with weak induction of dyskinesia [132]. Interestingly, no worsening of 
dyskinetic movements  was observed over a 5 day treatment period with KW 
6002 plus L-DOPA, further supporting a potential palliative effect of A2A 
antagonists in the treatment of established dyskinesias (Tab. 1). 
 The study of the effects of A2A antagonists on behavioural parameters in 
both rat and primate dyskinesia models has been paralleled by the analysis of 
the influence of A2A blockade on the  biochemical modifications induced by 
chronic L-DOPA in the BG of 6-OHDA-lesioned rats (Tab. 1). Prolonged 
administration of L-DOPA, according to a regimen capable of inducing a 
sensitized (dyskinetic-like) rotational response, has been shown to modify the 
expression of the neuropeptides ENK and DYN as well as of the enzyme 
glutamic acid decarboxylase (GAD67) in the BG of 6-OHDA-lesioned rats 
[155-159]. Thus, although a direct relationship between these biochemical 
changes and L-DOPA-induced dyskinesia onset has not been univocally 
demonstrated, they have nevertheless been postulated to reflect a more general 
aberrant functionality of BG produced by long-term L-DOPA, which is 
thought to underlie the dyskinesia elicited by this drug [160].  
 Coadministration of low doses of L-DOPA with the A2A antagonist SCH 
58261 did not induce  modifications in the striatal levels of ENK, DYN and 
GAD67 produced by chronic higher doses of L-DOPA in 6-OHDA-lesioned 
rats [158] (Tab. 1). Similarly, no changes in GAD67 levels were induced by 
chronic SCH 58261 plus L-DOPA in the GP [159]. 
 Moreover, beneficial effects of A2A blockade on the regulation of the 
phosphorylation state of the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) type of glutamate receptors by L-DOPA have been described. 
Chronic administration of L-DOPA to 6-OHDA-lesioned rats leads to 
hyperphosphorilation of the striatal AMPA receptor, an effect that has been 
postulated to participate in the genesis of L-DOPA-induced dyskinesias, being 
prevented by co administration of KW 6002 [151,161] (Tab. 1). Taken together, 
these biochemical outcomes indicate that A2A blockade extensively regulates the 
functionality of BG circuits and modulates the neuronal responsiveness to L-
DOPA, suggesting that these actions might be involved in the beneficial 
behavioural effects of A2A antagonists observed in animal models of dyskinesia. 
 The neuronal mechanisms underlying the regulation of BG activity by A2A 
antagonists might involve both post- and presynaptic A2A receptors. Thus, 
modulation of striatal neuronal functionality by regulation of postsynaptic 
receptor and kinases [162] or the modulation of neurotransmitter release [25], 
might influence BG neuroplasticity as well and, in turn, the onset of dyskinesia. 
 In addition to the postulated A2A receptor regulatory effects on neuronal 
responsiveness following prolonged dopaminergic stimuli, it should be 
considered that A2A antagonists, by potentiating the motor effects of L-DOPA 
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or dopaminergic drugs allow the latter to be used at low non-dyskinetic doses 
[124,125,132,147]. Therefore, the sparing of dopaminomimetic agents 
produced by coadministration with A2A antagonists might contribute towards 
reducing, or at least delaying, the onset of neuroplastic modifications in the 
BG, thus enabling maintenance therapy with the above drugs at doses 
presenting a reduced incidence of dyskinetic effects. 
 Taken together, data obtained from several preclinical studies point to the 
existence of beneficial effects for chronic A2A antagonists on PD motor 
disability and on motor complications produced by long-term L-DOPA. These 
effects are of considerable interest in light of the fact that motor complications 
are one of the intrinsic limits of L-DOPA therapy and are often insensitive to 
pharmacological manipulation. Moreover, lack of tolerance to the motor 
effects of A2A antagonists suggests that these drugs can be successfully used 
over long periods, rendering them particularly suitable for a prolonged 
pharmacological treatment such as that required in PD. 
 
Effects on parkinsonian tremor and muscle rigidity: Animal 
models 
 Resting tremor is one of the earliest symptoms manifested by parkinsonian 
patients and, interestingly, recent studies have indicated that A2A antagonists 
exert beneficial effects in rat models of parkinsonian tremor. 
 The antitremorigenic properties of drugs can be evaluated in experimental 
animals by measuring their ability in counteracting tremulous jaw movements 
induced in rats by a wide number of pharmacological agents, ranging from the 
DA receptor antagonist haloperidol to cholinomimetic drugs, such as tacrine or 
pilocarpine [163]. Although human parkinsonian resting tremor mainly affects 
the hands and is less frequently observed in the jaw, rat tremulous jaw movements 
have been shown to share many electromyographic and pharmacological 
characteristics with parkinsonian tremor, including frequency (3-7 Hz), 
responsiveness to common antiparkinsonian drugs and striatal origin [163-165]. 
 Acute administration of the A2A antagonist SCH 58261 reversed jaw 
tremor stimulated by tacrine in rats [166] and, accordingly A2A blockade by KF 
17837 was found to effectively counteract tremulous jaw movements induced 
by haloperidol [167] (Tab. 1). Moreover, analysis of the striatal sites involved 
in the counteraction of tremor by A2A antagonists has evidenced a critical role 
for the ventrolateral striatum in this effect. Thus, an almost complete 
suppression of tacrine-induced tremulous jaw movements has been observed 
following the infusion of the A2A antagonist SCH BT2 into the ventrolateral 
striatum, whereas only a partial effect was produced if SCH BT2 was infused 
into the dorsomedial striatum [166]. Notably, rat tremulous jaw movements 
have been shown to originate mainly at the level of the ventrolateral striatum 
[163], therefore the site-dependence of the antitremorigenic effects of A2A 
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antagonists likely reflects a direct suppressive effect of these drugs on the 
genesis of tremor.  
 On the basis that striatal acetylcholine plays a critical role in promoting the 
genesis of tremulous jaw movements [163], it has been hypothesised that 
modulation of cholinergic transmission by A2A antagonists might underlie the 
antitremorigenic effects of these drugs observed in rats. The postulated 
interactions between A2A antagonists and acetylcholine occur mainly at the 
presynaptic level, where blockade of A2A receptors located on striatal 
cholinergic interneurons is known to reduce acetylcholine outflow [134,135]. 
On the other hand, postsynaptic cholinergic mechanisms do not seem to be 
involved, since blockade of A2A receptors by SCH 58261 was found to be 
ineffective in reversing jaw tremor stimulated by the direct muscarinic agonist 
pilocarpine [168]. However, since several other neurotransmitters, including 
DA, GABA and glutamate, are known to regulate the expression of tremulous 
jaw movements in rats [163,169], interactions between A2A receptors and DA, 
as well as the influence of A2A antagonists on neurotransmitters other than 
acetylcholine and DA might be involved in the antitremorigenic effect of these 
drugs. 
 Muscle rigidity is a characteristic symptom of PD, in addition to tremor and 
akinesia. Administration of adequate doses of haloperidol or reserpine to rats 
induces muscle rigidity sharing many mechano- and electromyographic features 
with that observed in PD patients [170]. Acute blockade of A2A receptors by 
SCH 58261 was found to effectively counteract parkinsonian-like muscle 
rigidity in rats, affecting both mechano- and electromyographic components of 
the rigidity [171] (Tab. 1), an effect that has been proposed to be mediated by the 
facilitation of DA transmission at the postsynaptic level [171,172]. 
 Taken together, the effects of A2A antagonists obtained in PD animal 
models indicate that these drugs not only ameliorate motor impairment, but 
also effectively counteract parkinsonian-like resting tremor and muscle 
rigidity. Notably, these latter effects are of particular interest for a potential 
clinical use of A2A antagonists since, in parkinsonian patients, resting tremor 
and muscle rigidity are often insensitive to  classic antiparkinsonian 
medications. 
 
Effects of adenosine A2A antagonists in parkinsonian 
patients: Results from clinical trials 
 A first evaluation of the potential antiparkinsonian effect produced in 
humans by the manipulation of adenosine receptors has been performed using 
the non specific antagonists theophylline and caffeine. The results obtained in 
these early clinical trials, although evidencing several positive effects, were 
however contradictory.  
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 Long-term administration of theophylline was found to ameliorate 
parkinsonian motor disability and to counteract resting tremor [173,174]. In 
patients with advanced PD, coadministration of theophylline has been reported 
to extend the duration of the L-DOPA “on” period [175], but this result has not 
yet been definitively confirmed [176]. Moreover, in both these latter reports, a 
worsening, rather than improvement, of resting tremor was described 
following theophylline administration [175,176]. In a similar way, clinical 
evaluation of caffeine did not definitively demonstrate an antiparkinsonian 
effect for this drug [177,178]. However, it should be noted that clinical trials 
have often employed high doses of either caffeine or theophylline which are 
known to induce motor depression, rather than stimulation [179,180]. 
Therefore, on one hand early clinical trials suggested the existence of potential 
beneficial effects by adenosine receptor blockade in parkinsonian patients, whilst 
on the other, underlined the need to use more effective specific compounds. 
 The development of new selective antagonists towards A2A receptors and 
their encouraging effects in animal models of PD have provided a rationale for 
the re-evaluation of adenosine antagonists as potential antiparkinsonian drugs 
in humans. Accordingly, the large body of evidence available on the effects of 
A2A antagonists in PD patients has been obtained using the compound KW 
6002 (also called istradefylline), currently in stage III of clinical evaluation. 
Results obtained in patients treated with KW 6002 largely confirm findings 
observed following administration of A2A antagonists to parkinsonian rodents 
and primates, although discrepancies have been reported [101,181]. 
 In an initial trial, the effects of KW 6002, given either alone or in 
combination with intravenous L-DOPA, have been evaluated in patients with 
advanced PD [161,182]. When administered as monotherapy, KW 6002 
neither improved motor impairment nor induced dyskinesias per se. Moreover, 
coadministration of KW 6002 did not modify the motor effects and dyskinesia 
stimulated by an optimal dose of L-DOPA, although a longer duration of the 
L-DOPA “on” phase was described [98]. On the other hand, combined 
administration of KW 6002 plus a suboptimal dose of L-DOPA resulted in a 
significant improvement of motor disability comparable to that produced by an 
optimal dose of L-DOPA, being however associated with a lesser degree of 
dyskinesias [161]. The combination of KW 6002 plus the low dose of L-
DOPA ameliorated all cardinal symptoms of PD, in particular resting tremor 
[161,182]. In agreement with the results obtained using KW 6002, potentiation 
of the effects of L-DOPA has recently been reported in PD patients following 
coadministration with the novel A2A antagonist SCH 420814 [183]. 
 The ineffectiveness of KW 6002 monotherapy in counteracting 
parkinsonian symptoms in humans is at variance with results obtained in 
animals, in which KW 6002 reverted motor disability when given alone 
[114,131-133]. A possible explanation for this discrepancy may depend on the 
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fact that the doses used in clinical trials have been too low and that higher 
doses of KW 6002 could exert antiparkinsonian activity as a monotherapy. 
Moreover, it should be taken into account that clinical trials have been 
performed in patients with advanced PD, presumably associated with 
considerable dopaminergic degeneration. Therefore, it may be hypothesised 
that residual endogenous DA might be fundamental in obtaining a complete 
expression of the antiparkinsonian effects produced by A2A receptor blockade, 
thus justifying the ineffectiveness of KW 6002 when administered alone.  
 A major finding emerging from the clinical evaluation of KW 6002 is 
represented by its ability to extend the duration of L-DOPA “on” phase 
[98,182]. Further studies in patients experiencing L-DOPA motor fluctuations 
have confirmed this result, showing however that the effect was coupled with 
an enhancement in L-DOPA-induced dyskinesias [98,184,185]. This latter 
finding appears to contradict primate studies in which KW 6002 was found to 
potentiate the effects of L-DOPA without exacerbating dyskinesia [132]. 
Nevertheless, a close examination of the characteristic features of dyskinesia 
has highlighted how KW 6002 prolonged the duration of the “on” phase 
associated with the so called “non-troublesome” dyskinesia, whereas the 
duration of the “on” phase associated with “troublesome” dyskinesia was 
unaltered following KW 6002. Furthermore, the overall severity of L-DOPA-
induced dyskinesia was not exacerbated by KW 6002 [98]. Therefore, the 
enhancement of dyskinesia produced by KW 6002 does not seem to preclude 
the use of either this drug or, generally, of other A2A antagonists in human PD 
treatment.  
 In addition to beneficial motor effects, clinical trials have demonstrated 
that KW 6002 is well tolerated, the only adverse effects reported being nausea, 
increased stiffness and headache, which however were reported to be of mild 
intensity and which resolved spontaneously during treatment [98,184]. Similar 
results have been reported for the novel A2A antagonists SCH 420814 [183] 
suggesting that this class of drugs is suited for use in long-term 
pharmacological treatment.  
 Taken together, the outcomes deriving from clinical trials performed in 
humans illustrate an encouraging therapeutic potential for A2A antagonists in 
the treatment of PD. Indeed, the observed temporal extension of the L-DOPA 
“on” phase is of particular interest, since the progressive shortening of L-
DOPA motor effects (“wearing off”) represents one of the main 
inconveniences manifested during prolonged use of this drug. Nevertheless, 
further studies involving early stage parkinsonian patients are required to 
clarify whether A2A antagonists are suited for use in monotherapy. 
Furthermore, assessment of these drugs in patients devoid of L-DOPA motor 
complications should be performed in order to evaluate in detail the effect of 
A2A antagonists on human dyskinesia onset and development.  
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Potential neuroprotective effect of A2A antagonists in 
Parkinson’s disease 
 One of the major limitations of the current pharmacological treatment of 
PD is represented by its substantial ineffectiveness in counteracting the 
degeneration of dopaminergic neurons which underlies this condition, 
therefore the search for therapeutic strategies capable of arresting, or at least 
slowing down, this process is of paramount importance. Consequently, it has 
recently been emphasised that the blockade of adenosine A2A receptors might 
potentially represent a valuable approach in counteracting neuronal death in PD. 
 Previous studies have proposed that, in the brain, adenosine A2A receptors 
critically regulate neuronal survival in response to neurotoxic insults 
[186,187], ranging from ischemia [188-190] to excitotoxicity [191,192].  
 Notably, neuroprotection by A2A receptor blockade has also been 
described in rodent models of neurodegenerative diseases. Administration of 
A2A antagonists has been shown to counteract striatal degeneration in a rat 
model of Huntington’s disease [193] and to prevent β-amyloid-induced 
neurotoxicity in cultures of rat cerebellar cells, a putative model of 
Alzheimer’s disease [194]. Moreover, interesting results demonstrating 
neuroprotective effects by A2A blockade have been obtained in the mouse 
model of MPTP-induced parkinsonian-like neurodegeneration. In this 
paradigm, administration of the non selective adenosine antagonist caffeine or 
of specific A2A, but not A1, antagonists was found to elicit robust 
neuroprotection, preventing the loss of striatal DA and of nigral dopaminergic 
neurons induced by MPTP [99,195-197] (Tab. 1). Consistently, neuroprotective 
effects of A2A antagonists have been described in complementary experiments 
using the 6-OHDA rat model of dopaminergic neurodegeneration [198] (Tab. 1). 
Notably, data deriving from pharmacological studies have been substantiated by 
genetic experiments demonstrating a prevention of MPTP-induced neurotoxicity 
by the deletion of the A2A receptor in mice [99]. 
 The mechanisms by which A2A receptor blockade elicits protective effects 
in models of PD neurotoxicity are not fully known; however, experimental 
evidence has suggested that glutamate might be involved in this effect 
[101,187], being considered a facilitator of the neurotoxic dysfunctions that 
form the base for PD neurodegeneration [199-201]. Interestingly, A2A 
receptors, located on either presynaptic glutamatergic terminals or glial cells 
[10,11,18], have been shown to modulate glutamate extracellular 
concentrations extensively in several brain areas including BG. In particular, 
stimulation of A2A receptors enhances glutamate release which, in contrast, is 
reduced following A2A blockade [202,203]. Based on the above, it has been 
hypothesised that A2A receptor blockade might result in a relief of 
glutamatergic output to DA SNc neurons and, in turn, in a reduction of PD 
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neurodegeneration [187]. Nevertheless, in view of the large number of 
neuronal functions regulated by A2A receptors [25], it is possible to maintain 
that mechanisms other than modulation of glutamate release might be involved 
in the neuroprotective effect of A2A antagonists. 
 To date, no studies have been performed to evaluate the exerting of 
beneficial effects by A2A antagonists in human PD neurodegeneration. 
Nevertheless, the protective effects of A2A receptor blockade observed in 
animal models of parkinsonian-like neurotoxicity are of particular interest in 
light of epidemiological research demonstrating the existence of an inverse 
relationship between caffeine consumption and incidence of PD [204,205]. 
Indeed, although these studies have not demonstrated the ability of caffeine to 
prevent the onset of PD conclusively [101], it is conceivable that the inverse 
relationship between caffeine consumption and PD might be due to 
neuroprotective effects on dopaminergic mesencephalic neurons subsequent to 
persistent A2A receptor blockade by caffeine. Therefore, direct evidence of 
neuroprotection mediated by A2A receptor antagonists in animals, as well as 
data from epidemiological studies, provide new insights into the study of the 
antiparkinsonian potential of these drugs. It can therefore be postulated that 
A2A receptor antagonists might not only relieve motor deficits in established 
PD, but also potentially prevent the progress of the pathology by arresting 
degeneration of dopaminergic mesencephalic neurons. 
 Although neuroprotective effects represent an intriguing feature of the 
antiparkinsonian activity of A2A antagonists, it should however be highlighted 
that A2A receptor blockade might produce side effects outside the brain. 
Indeed, stimulation of A2A receptors has been demonstrated to reduce renal and 
cardiac damage during ischemia [206-208] and to attenuate inflammatory 
processes [209,210]. Moreover, neuroprotective effects have been observed in 
the spinal cord following A2A receptor stimulation [211], thus indirectly 
accounting for potential negative effects of A2A blockade at this level. Further 
studies should be carried out both in animals and humans in order to evaluate 
all the possible implications of A2A receptor blockade, with the specific aim of 
clarifying whether, and under which circumstances, A2A antagonists might be 
used as neuroprotective agents in PD patients. 
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